AU
AURA.US Aura Biosciences Inc
- Market cap
- USD 740M
- P/E
- -
- P/B
- 2.58x
- ROE
- -51.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is AURA.US undervalued?
Graham numberThe Graham number of Aura Biosciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aura Biosciences Inc fundamental analysis
No fundamental analysis for Aura Biosciences Inc yet.
Aura Biosciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Aura Biosciences Inc
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology …
Full company profileAura Biosciences Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Aura Biosciences Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -509K | -831K | -835K | -1.18M | -1.30M | -1.22M | - | - |
| Operating Income | -24.1M | -22.2M | -35.3M | -60.3M | -85.0M | -96.1M | -113M | -157M |
| EBITDA | -23.7M | -21.4M | -34.4M | -57.6M | -75.0M | -85.6M | -105M | -155M |
| Net Income | -24.2M | -22.2M | -35.3M | -58.8M | -76.4M | -86.9M | -106M | -149M |
| EPS | -0.01 | -0.76 | -1.21 | -1.96 | -1.93 | -1.75 | -1.76 | -1.34 |
| Balance Sheet | ||||||||
| Total Assets | 37.1M | 22.1M | 160M | 224M | 255M | 183M | 169M | 322M |
| Total Liabilities | 6.29M | 2.74M | 7.72M | 28.4M | 29.2M | 30.5M | 32.5M | 34.2M |
| Shareholders' Equity | 30.8M | 19.4M | 152M | 196M | 226M | 152M | 137M | 287M |
| Cash & Short-term Investments | 32.5M | 17.4M | 149M | 189M | 226M | 151M | 144M | 297M |
| Total Debt | 49.0K | 15.0K | 975K | 20.9M | 19.6M | 18.8M | 17.4M | 16.2M |
| Cash Flow | ||||||||
| Operating Cash Flow | -20.7M | -24.3M | -32.4M | -54.6M | -63.8M | -79.8M | -84.7M | -118M |
| Capital Expenditure | 2.22M | 771K | 2.13M | 1.09M | 709K | 1.25M | 447K | 271K |
| Free Cash Flow | -22.9M | -25.1M | -34.5M | -55.7M | -64.6M | -81.1M | -85.2M | -119M |
| Ratios | ||||||||
| ROE | -78.7% | -114.7% | -23.1% | -30.0% | -33.8% | -57.2% | -77.6% | -51.7% |
| ROA | -65.3% | -100.5% | -22.0% | -26.2% | -30.0% | -47.6% | -62.7% | -46.2% |
| Debt to Equity | 0.00x | 0.00x | 0.01x | 0.11x | 0.09x | 0.12x | 0.13x | 0.06x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Aura Biosciences Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | USD 39.8M | 0.01 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Aura Biosciences Inc
- Insiders 2.52%
- Institutions 97.48%
- Public & others 0.00%
- Shares outstanding 104M
- Free float 75.0M
Top funds holding AURA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 2.80M | 2.70% | -5.46% | Sep 2026 |
| iShares Russell 2000 ETF | 1.44M | 1.39% | 0.00% | Oct 2026 |
| Franklin Biotechnology Discv A(acc)USD | 1.31M | 1.26% | 0.00% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 1.01M | 0.97% | +2.69% | Oct 2026 |
| Franklin Biotechnology Discovery A | 766K | 0.74% | 0.00% | Sep 2026 |
| iShares Biotechnology ETF | 518K | 0.50% | -0.19% | Oct 2026 |
| iShares Russell 2000 Growth ETF | 506K | 0.49% | -0.38% | Oct 2026 |
| Fidelity Small Cap Index | 493K | 0.48% | +0.82% | Aug 2026 |
| Fidelity Extended Market Index | 445K | 0.43% | -7.89% | Sep 2026 |
| Biotech Growth Ord | 417K | 0.40% | 0.00% | Jul 2026 |
| Fidelity Enhanced Small Cap Core ETF | 340K | 0.33% | +0.27% | Oct 2026 |
| Vanguard Russell 2000 ETF | 338K | 0.33% | +30.70% | Sep 2026 |
| Vanguard Health Care ETF | 254K | 0.25% | +0.11% | Sep 2026 |
| Vanguard Explorer Inv | 187K | 0.18% | 0.00% | Sep 2026 |
| iShares Core S&P Total US Stock Mkt ETF | 183K | 0.18% | +0.03% | Oct 2026 |
| Fidelity Total Market Index | 183K | 0.18% | -0.05% | Sep 2026 |
| Dimensional US Small Cap ETF | 182K | 0.18% | 0.00% | Oct 2026 |
| iShares Micro-Cap ETF | 175K | 0.17% | 0.00% | Oct 2026 |
| Fidelity Series Total Market Index | 150K | 0.15% | 0.00% | Sep 2026 |
| DFA U.S. Small Cap I | 146K | 0.14% | +2.45% | Sep 2026 |
Top institutions holding AURA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| TCG Crossover Management, LLC | 9.53M | 9.21% | 0.00% | Jun 2026 |
| Suvretta Capital Management, LLC | 7.21M | 6.96% | +64.79% | Jun 2026 |
| Frazier Life Sciences Management, L.P. | 7.10M | 6.86% | +39.22% | Jun 2026 |
| Nantahala Capital Management, LLC | 5.90M | 5.70% | +178.70% | Jun 2026 |
| Long Focus Capital Management, LLC | 5.12M | 4.95% | +10.82% | Jun 2026 |
| BlackRock Inc | 4.71M | 4.55% | +31.26% | Jun 2026 |
| Adage Capital Partners Gp LLC | 4.64M | 4.48% | -4.94% | Jun 2026 |
| Caligan Partners LP | 4.30M | 4.15% | +1,769.91% | Jun 2026 |
| Vanguard Capital Management, LLC | 4.10M | 3.96% | +82.74% | Jun 2026 |
| FCPM III SERVICES BV | 4.05M | 3.92% | 0.00% | Jun 2026 |
| Orbimed Advisors LLC | 3.33M | 3.22% | 0.00% | Jun 2026 |
| Medicxi Ventures Management (Jersey) Ltd | 3.04M | 2.94% | 0.00% | Jun 2026 |
| RA Capital Management, LLC | 2.50M | 2.42% | 0.00% | Jun 2026 |
| Jupiter Topco LLC | 2.50M | 2.42% | 0.00% | Jun 2026 |
| Balyasny Asset Management LLC | 2.35M | 2.28% | +322.24% | Jun 2026 |
| Franklin Templeton Inc | 2.07M | 2.00% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 1.75M | 1.70% | +33.86% | Jun 2026 |
| Redmile Group, LLC | 1.67M | 1.61% | 0.00% | Jun 2026 |
| EcoR1 Capital, LLC | 1.67M | 1.61% | 0.00% | Jun 2026 |
| Trails Edge Capital Partners, LP | 1.44M | 1.39% | 0.00% | Jun 2026 |
Aura Biosciences Inc company profile
- Company name
- Aura Biosciences Inc
- Ticker
- AURA.US
- Exchange
- USA Stocks
- Listed since
- Oct 29, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 113
- Fiscal year end
- December
- Address
- 80 Guest Street, Boston, MA, United States, 02135
- Phone
- 617 500 8864
- Website
- aurabiosciences.com
About Aura Biosciences Inc
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Aura Biosciences Inc management
9- Dr. J. Jill Hopkins M.D.Chief Medical Officer & President of Research and Development · born 1965
- Ms. Natalie C. HollesPresident, CEO & Director · born 1973
- Ms. Amy ElazzouziSenior Vice President of Finance, Treasurer and Secretary · born 1974
- Ms. Susan Abu-Absi Ph.D.Chief Operating Officer
- Alex DasallaHead of Investor Relations & Corporate Communications
- Ms. Julie PersonChief People Officer · born 1974
- Mr. Patrick NealonSenior Vice President of Clinical Development Operations
- Dr. Anthony Daniels M.D.VP & Therapeutic Area of Head Ocular Oncology
- Ms. Erica Kratz Ph.D.Chief Regulatory & Quality Officer